1. Market Research
  2. > Oncology
4 reports for Salicylic Acid (page 1)

Purchase Reports From Reputable Market Research Publishers

Competitor Analysis: Biosimilar and Biosuperior Anti-TNF Antibodies – 2016 Update

  • $ 570
  • May 2016
  • 124 pages

Amgen Annual Report 2015 - Initiated phase III study in the US sBLA Antibody II Kawasaki Disease ClinicalTrials. gov Dec 2015 - Investigator-sponsored study to determine whether Enbrel when used in conjunction with IVIG and aspirin, improves treatment response to IVIG in patients with Kawas

  • Biosimilar
  • Salicylic Acid
  • Amgen Inc.
  • Merck & Co., Inc.
  • Pfizer Inc.

Competitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies – 2016 Update

  • $ 1482
  • May 2016
  • 462 pages

Amgen Annual Report 2015 - Initiated phase III study in the US sBLA Message Antibody II Kawasaki Disease ClinicalTrials. gov Dec 2015 - Investigator-sponsored study to determine whether Enbrel when used in conjunction with IVIG and aspirin, improves treatment response to IVIG in patients wi

  • Biosimilar
  • Pharmaceutical
  • Salicylic Acid
  • Pfizer Inc.
  • Roche Group

Competitor Analysis: TNF Antibodies 2015– Biosimilars and Biosuperiors of Humira, Remicade and Enbrel

  • $ 570
  • March 2015
  • 107 pages

ClinicalTrials. gov Sep 2014 - Investigator-sponsored study to determine whether Etanercept (Enbrel) when used in conjunction with IVIG and aspirin, improves treatment response to IVIG in patients with Kawasaki Disease.

  • Biosimilar
  • Salicylic Acid
  • AbbVie Inc.
  • Amgen Inc.
  • Delenex Therapeutics AG

Competitor Analysis: Therapeutic Antibodies 2015 - Biosimilars & Biosuperiors

  • $ 1482
  • April 2015
  • 414 pages

ClinicalTrials. gov Sep 2014 - Investigator-sponsored study to determine whether Etanercept (Enbrel) when used in conjunction with IVIG and aspirin, improves treatment response to IVIG in patients with Kawasaki Disease.

  • Biosimilar
  • Pharmaceutical
  • Salicylic Acid
  • Amgen Inc.
  • Biogen Idec Inc.


View report >

Hospital Social Impact in Texas (USA)

  • January 2019
  • 70 pages

OF ##, ## MI CASES SEEN BETWEEN 2008 AND 2018, ##. ##% WERE PRESCRIBED ASPIRIN WITHIN THE FIRST ## HOURS OF EITHER FIRST MEDICAL CONTACT OR HOSPITAL ARRIVAL, ##. ##% WERE NOT PRESCRIBED ASPIRIN, AND ##. ##% HAD CONTRAINDICATIONS TO ASPIRIN USE (PG. ##).

  • Health Services
  • Heart Attack
  • Hospital
  • Salicylic Acid
  • United States

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on